 Barbara Frederick
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 11 | 2020 | 604 | 1.270 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 115 | 0.760 |
Why?
| | Phthalazines | 2 | 2020 | 45 | 0.710 |
Why?
| | Cetuximab | 2 | 2020 | 95 | 0.710 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 50 | 0.670 |
Why?
| | DNA Repair | 2 | 2020 | 231 | 0.630 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 387 | 0.630 |
Why?
| | Piperazines | 2 | 2020 | 350 | 0.610 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 434 | 0.610 |
Why?
| | Quinazolines | 3 | 2007 | 250 | 0.520 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2014 | 683 | 0.490 |
Why?
| | ErbB Receptors | 5 | 2020 | 613 | 0.450 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2025 | 47 | 0.390 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2025 | 868 | 0.340 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 259 | 0.330 |
Why?
| | Mice, Nude | 7 | 2020 | 696 | 0.320 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2007 | 108 | 0.300 |
Why?
| | Cell Line, Tumor | 12 | 2025 | 3405 | 0.300 |
Why?
| | Piperidines | 2 | 2007 | 206 | 0.280 |
Why?
| | Smad4 Protein | 2 | 2020 | 38 | 0.250 |
Why?
| | Mesoderm | 1 | 2007 | 144 | 0.250 |
Why?
| | Protein Biosynthesis | 4 | 2025 | 430 | 0.250 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1231 | 0.240 |
Why?
| | Neoplasms | 4 | 2023 | 2643 | 0.220 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 226 | 0.220 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 301 | 0.220 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 155 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 800 | 0.190 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 1076 | 0.190 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 158 | 0.180 |
Why?
| | Epithelial Cells | 1 | 2007 | 1094 | 0.170 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 20 | 0.170 |
Why?
| | Proof of Concept Study | 1 | 2020 | 78 | 0.170 |
Why?
| | Clone Cells | 1 | 2020 | 266 | 0.170 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 164 | 0.170 |
Why?
| | Apoptosis | 5 | 2025 | 2551 | 0.160 |
Why?
| | Drug Synergism | 1 | 2020 | 382 | 0.160 |
Why?
| | Drosophila melanogaster | 2 | 2012 | 233 | 0.160 |
Why?
| | Prostatic Neoplasms | 3 | 2013 | 1034 | 0.150 |
Why?
| | Cisplatin | 1 | 2020 | 320 | 0.150 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2122 | 0.150 |
Why?
| | Mice | 10 | 2025 | 17757 | 0.150 |
Why?
| | Radiation, Ionizing | 3 | 2012 | 80 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2008 | 2489 | 0.140 |
Why?
| | Animals | 15 | 2025 | 36847 | 0.130 |
Why?
| | DNA Damage | 3 | 2020 | 420 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1396 | 0.120 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 43 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 399 | 0.120 |
Why?
| | Stromal Cells | 1 | 2014 | 112 | 0.110 |
Why?
| | N-Glycosyl Hydrolases | 2 | 2004 | 6 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2014 | 96 | 0.110 |
Why?
| | Adherens Junctions | 1 | 2013 | 25 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 194 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2014 | 195 | 0.100 |
Why?
| | Plant Proteins | 2 | 2004 | 113 | 0.100 |
Why?
| | Signal Transduction | 6 | 2014 | 5076 | 0.100 |
Why?
| | Sulfones | 1 | 2013 | 110 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Exosomes | 1 | 2013 | 103 | 0.100 |
Why?
| | Prostate | 1 | 2013 | 175 | 0.100 |
Why?
| | Glycine | 1 | 2013 | 175 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2012 | 103 | 0.090 |
Why?
| | Radiotherapy | 1 | 2012 | 201 | 0.090 |
Why?
| | Stilbenes | 1 | 2011 | 35 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4282 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 41 | 0.090 |
Why?
| | Maytansine | 1 | 2011 | 16 | 0.090 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2011 | 66 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1682 | 0.090 |
Why?
| | Paclitaxel | 1 | 2012 | 227 | 0.090 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 507 | 0.080 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 23 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 86 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 766 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 584 | 0.070 |
Why?
| | Humans | 20 | 2025 | 136765 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2009 | 137 | 0.070 |
Why?
| | Up-Regulation | 2 | 2014 | 844 | 0.070 |
Why?
| | Glutathione | 1 | 2009 | 356 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2025 | 2475 | 0.070 |
Why?
| | Receptors, LHRH | 2 | 2004 | 14 | 0.070 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2011 | 190 | 0.070 |
Why?
| | Cortactin | 1 | 2006 | 8 | 0.070 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2006 | 9 | 0.070 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2006 | 59 | 0.060 |
Why?
| | Hypoxia | 1 | 2013 | 1112 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2009 | 322 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 328 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 664 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 796 | 0.060 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 362 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 139 | 0.050 |
Why?
| | Immunotoxins | 1 | 2004 | 55 | 0.050 |
Why?
| | Cell Cycle | 2 | 2020 | 601 | 0.050 |
Why?
| | Female | 5 | 2020 | 72795 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 916 | 0.050 |
Why?
| | Drug Discovery | 1 | 2023 | 141 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2003 | 212 | 0.050 |
Why?
| | Carcinoma | 1 | 2003 | 238 | 0.050 |
Why?
| | Phosphorylation | 1 | 2025 | 1758 | 0.040 |
Why?
| | Mutation | 4 | 2013 | 3946 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | HCT116 Cells | 2 | 2011 | 80 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 141 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 268 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 225 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 953 | 0.040 |
Why?
| | Cell Line | 1 | 2023 | 2838 | 0.030 |
Why?
| | Transfection | 2 | 2011 | 941 | 0.030 |
Why?
| | Veratrum Alkaloids | 1 | 2014 | 19 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3265 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 25 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 35 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1116 | 0.030 |
Why?
| | Ribosome Inactivating Proteins, Type 1 | 2 | 2004 | 3 | 0.030 |
Why?
| | Annexin A2 | 1 | 2013 | 11 | 0.030 |
Why?
| | Tetraspanins | 1 | 2013 | 19 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 633 | 0.030 |
Why?
| | Metalloproteases | 1 | 2013 | 43 | 0.030 |
Why?
| | CHO Cells | 2 | 2004 | 161 | 0.030 |
Why?
| | Cricetinae | 2 | 2004 | 289 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1058 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 239 | 0.030 |
Why?
| | Models, Biological | 2 | 2012 | 1773 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2013 | 142 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 95 | 0.030 |
Why?
| | Blotting, Western | 2 | 2007 | 1225 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 226 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 209 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2013 | 126 | 0.020 |
Why?
| | Penis | 1 | 2012 | 36 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 39 | 0.020 |
Why?
| | Testis | 1 | 2012 | 151 | 0.020 |
Why?
| | Comet Assay | 1 | 2011 | 16 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 412 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4013 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 366 | 0.020 |
Why?
| | Glioma | 1 | 2015 | 395 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 87 | 0.020 |
Why?
| | BRCA1 Protein | 1 | 2011 | 76 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 306 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4191 | 0.020 |
Why?
| | Spindle Apparatus | 1 | 2011 | 102 | 0.020 |
Why?
| | Larva | 1 | 2011 | 224 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 192 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 647 | 0.020 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 372 | 0.020 |
Why?
| | Cytoprotection | 1 | 2009 | 56 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 613 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 324 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 968 | 0.020 |
Why?
| | Proteome | 1 | 2013 | 472 | 0.020 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2008 | 12 | 0.020 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2008 | 12 | 0.020 |
Why?
| | GRB2 Adaptor Protein | 1 | 2008 | 13 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 215 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 371 | 0.020 |
Why?
| | Luciferases | 1 | 2008 | 149 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2009 | 170 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 434 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1321 | 0.020 |
Why?
| | Skin | 1 | 2012 | 751 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 268 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 597 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 528 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1733 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2486 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 257 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 810 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1718 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1235 | 0.020 |
Why?
| | Gene Amplification | 1 | 2006 | 104 | 0.020 |
Why?
| | Histones | 1 | 2011 | 636 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 317 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 428 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2006 | 523 | 0.010 |
Why?
| | Colony-Forming Units Assay | 1 | 2004 | 91 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1269 | 0.010 |
Why?
| | Actins | 1 | 2006 | 416 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2003 | 34 | 0.010 |
Why?
| | Male | 4 | 2013 | 67311 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5639 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2004 | 148 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1314 | 0.010 |
Why?
| | Drug Combinations | 1 | 2003 | 343 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 981 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 735 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2003 | 951 | 0.010 |
Why?
| | Protein Binding | 1 | 2004 | 2216 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2003 | 2831 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 10745 | 0.010 |
Why?
|
|
Frederick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|